Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Idenix (IDIX) Patent Infringement Lawsuit Against Gilead, Progenics (PGNX) Topline Data From Study

Hepatitis means inflammation of the liver. There are many causes of hepatitis. For example, drinking too much alcohol, various drugs and chemicals, and also several different viruses can cause hepatitis.

Hepatitis C, a virus which is carried in the bloodstream to the liver, is one of several hepatitis viruses and is generally considered to be among the most serious of these viruses. Hepatitis C is passed through contact with contaminated blood — most commonly through needles shared during illegal-drug use.

Chronic hepatitis C is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States

On Friday, Gilead Sciences, Inc. reported that the FDA has approved Sovaldi(NYSE:TM) (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (NYSE:CHC) infection as a component of a combination antiviral treatment regimen.

The Wholesaler Acquisition Cost (WAC) of a 28-tablet bottle of Sovaldi in the United States is $28,000

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) recently reported that it has filed two lawsuits against Gilead: a patent infringement lawsuit in the U.S. District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the U.S. District Court in Wilmington, Delaware.

The Massachusetts infringement lawsuit alleges that Gilead infringes two U.S. patents co-owned by IDIX (6,914,054 and 7,608,597) that cover methods of treating the hepatitis C virus using 2'-methyl nucleosides. In this lawsuit, IDIX is seeking a declaration that Gilead's imminent distribution, importation, use, sale or offer to sell drugs-containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents.

The Delaware infringement and interference lawsuit alleges that Gilead infringes a separate U.S. patent co-owned by IDIX (7,608,600) that covers methods of treating the hepatitis C virus using 2'-methyl-2'-fluoro nucleosides. IDIX is seeking a declaration that Gilead's imminent distribution, importation, use, sale or offer to sell drugs-containing sofosbuvir infringes the IDIX '600 patent. Additionally, the Delaware lawsuit asserts a claim for interfering patents between the IDIX '600 patent and a U.S. patent (8,415,322) owned by a Gilead subsidiary, Gilead Pharmasset LLC. IDIX is seeking to have the Gilead '322 patent declared invalid.

IDIX is a biopharmaceutical Company engaged in the discovery and development of drugs-for the treatment of human viral diseases.

More about Idenix Pharmaceuticals, Inc. (IDIX) at


Crown Equity Holdings Inc. (OTCPK:CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher. The company is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States.


CRWE Network will allow users to connect with people who live in their community, and its business plan is based on selling advertising to local businesses..

CRWE Network‘s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

Community of Encinitas, CA, visit CRWE Network Encinitas at

Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar social networking service market with its CRWE Network (CRWE-PR) project.

More about Crown Equity Holdings Inc. (OTCPK:CRWE) at


Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in six will be diagnosed with prostate cancer in his lifetime.

The American Cancer Society estimates that approximately 240,000 new cases of prostate cancer will be diagnosed and about 30,000 men will die of the disease this year. Approximately 2 million men in the U.S. currently count themselves among prostate cancer survivors.

The successful development of an initial and ongoing treatment plan for the management of prostate cancer is often handicapped by the inability to accurately assess the presence, location, grade and extent of the disease. Accurate diagnosis and staging is imperative to avoid overtreatment of indolent disease, with its potential life changing side effects, including incontinence and impotence, and the underestimation of aggressive disease.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) reported that findings from a Phase I study of its Imaging Agent, 1404, were presented at the meeting of the Society for Urologic Oncology in Rockville, Maryland.

In this Phase I trial, according to PGNX, its imaging agent identified primary prostate cancer with a high degree of accuracy and, in addition, may have the ability to discriminate high grade prostate cancer from moderate and low grade disease. PGNX believes this is the kind of information men suffering from prostate cancer and their doctors need in order to best manage their disease.

PGNX is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development.

More about Progenics Pharmaceuticals, Inc. (PGNX) at


Read Full Disclaimer at

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.